Medium-Term Survival and Functional Status of Patients with Severe Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation  by Candiello, Alfonsina et al.
Rev Bras Cardiol Invasiva. 
2013;21(4):319-25
© 2013 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. All rights reserved.
Medium-Term Survival and Functional  
Status of Patients with Severe Aortic Valve Stenosis 
Undergoing Transcatheter Aortic Valve Implantation
Alfonsina Candiello1, Fernando Cura2, Mariano Albertal3, Lucio T. Padilla4, Gerardo Nau5,  
Florencia Castro6, Ricardo Ronderos7, Gustavo Avegliano8, Daniel Navia9, Jorge Belardi10
ABSTRACT
Background: Transcatheter aortic valve implantation (TAVI) is 
a treatment option for patients with aortic valve stenosis (AS) 
and high or prohibitive surgical risk. We report our experi-
ence using the Medtronic CoreValveTM self-expending system. 
Methods: From 2009 to 2013, 51 consecutive patients with 
severe symptomatic AS and high or prohibitive surgical risk 
were submitted to TAVI. Results were analyzed according 
to the criteria of the Valve Academic Research Consortium 
(VARC) –2. Results: Mean age was 82 ± 6 years, 49% were 
female, 19% were diabetic, 21% had renal failure and the 
logistic EuroScore was 17.4 ± 11.4%. The success rate of 
the device was 84.3%. All of the patients had a significant 
decrease of transaortic gradients, which was maintained over 
time. Hospitalization time was 6 days (interquartile range: 
5-8.8). In-hospital mortality at 30 days as 7.8% and 9.8%, 
respectively. Permanent pacemaker implantation was required 
in 32.6% of the cases; ischemic stroke was observed in 3.9% 
and major vascular complications in 6% of the patients. Survival 
at 6 months and 1 year was 86.3% and 84.4%, respectively. 
NYHA functional class improved significantly after TAVI and 
remained low in the medium-term follow-up. Conclusions: 
In this preliminary experience, the treatment of patients with 
AS and high or prohibitive surgical risk with TAVI, using the 
CoreValveTM self-expanding system was feasible and safe and 
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RESUMO
Sobrevivência a Médio Prazo e Estado Funcional  
de Pacientes com Estenose Valvar Aórtica  
Grave Submetidos a Implante Transcateter  
da Válvula Aórtica
Introdução: O procedimento de implante transcateter da válvula 
aórtica (TAVI, do inglês transcatheter aortic valve implantation) 
representa opção de tratamento em pacientes com estenose 
valvar aórtica (EA) com risco cirúrgico elevado ou proibitivo. 
Relatamos nossa experiência usando o sistema autoexpansível 
Medtronic CoreValve®. Métodos: No período de 2009 a 2013, 
51 pacientes consecutivos com EA grave sintomática e risco cirúr-
gico alto ou proibitivo foram submetidos ao TAVI. Os resultados 
foram analisados de acordo com os critérios Valve Academic 
Research Consortium (VARC) –2. Resultados: A média de idades 
dos pacientes foi 82 ± 6 anos, 49% eram do sexo feminino, 
19% diabéticos, 21% tinham insuficiência renal e o EuroSCORE 
logístico foi 17,4 ± 11,4%. O sucesso do dispositivo foi alcançado 
em 84,3%. Todos os pacientes tiveram diminuição significativa 
dos gradientes transaórticos, que foi mantida ao longo do tempo. 
A internação hospitalar foi de 6 dias (intervalo interquartil: 
5-8,8). A mortalidade intra-hospitalar e aos 30 dias foi 7,8% e 
9,8%, respectivamente. Implante de marca-passo permanente 
foi necessário em 32,6% dos casos; acidente cerebrovascular 
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led to sustained improvement of cardiac symptoms. After 
overcoming the initial risks of death and stroke, the procedure 
guaranteed good long-term clinical outcomes.
 
 
 
 
 
 
 
 
DESCRIPTORS: Aortic valve stenosis. Heart valve prosthesis 
implantation. Treatment outcome.
(including the assessment of the aortic ring) and the 
feasibility of a transfemoral approach.
Severe AS was defined as an area of the aortic 
valve < 0.8 cm2, besides a mean aortic valve gradient 
> 40 mmHg, or a maximal aortic jet velocity > 4.0 m/s. 
Patients were considered at high risk of surgical 
complications or death based on coexisting conditions 
associated with the risk of death of, at least, 15% at 30 
days after the procedure (Society of Thoracic Surgeons 
score [STS] ≥ 10 or Logistic EuroSCORE ≥ 15).
The anatomical inclusion criteria were as follows: 
orifice of the aortic valve with area < 0.8 cm2, diam-
eter of the aortic annulus ≥ 20 mm and ≤ 29 mm, 
and diameter of ascending aorta to the level of the 
sinotubular junction ≤ 45 mm.
Patients were excluded if there was intracavitary 
thrombus; extremely low (< 20%) and irreversible left 
ventricle ejection fraction (LVEF); severe mitral or aor-
tic regurgitation (4 +); iliofemoral arterial axis with a 
bore < 6 mm or severe tortuosity, which could prevent 
the delivery of the prosthesis; or low implantation of 
coronary ostium (< 10 mm).
The success of the device was defined as the 
absence of mortality in the procedure and a correct 
positioning of a single prosthesis in the proper location, 
and with adequate performance (no prosthesis-patient 
mismatch; mean aortic valve gradient < 20 mmHg or 
maximum speed < 3 m/s; and without moderate/severe 
regurgitation of the valve prosthesis).
All patients provided informed consent to be sub-
mitted to TAVI by transfemoral route, including consent 
for anonymous processing of their data. Information 
on death was obtained at the hospital or by telephone 
contact with the patient’s family. All events were defined 
according to the criteria from Valve Academic Research 
Consortium (VARC) –2.6
Implantation procedure
All procedures were performed under general anesthe-
sia, using the 18F self-expanding CoreValve® (Medtronic 
isquêmico ocorreu em 3,9%; e complicações vasculares maiores 
em 6% dos pacientes. A sobrevivência aos 6 meses e em 1 ano 
foi 86,3% e 84,4%, respectivamente. A classe funcional NYHA 
melhorou significativamente após o TAVI e permaneceu baixa 
no seguimento de médio prazo. Conclusões: Nesta experiência 
preliminar, o tratamento de pacientes com EA e risco cirúrgico 
alto ou proibitivo com TAVI, usando o sistema autoexpansível 
CoreValve®, foi considerado viável e seguro, e levou à melhoria 
sustentável dos sintomas cardíacos. Após a superação dos riscos 
iniciais de morte e de acidente cerebrovascular, o procedimento 
garantiu um bom resultado clínico, no longo prazo.
DESCRITORES: Estenose da valva aórtica. Implante de prótese 
de valva cardíaca. Resultado de tratamento.
T he calcified aortic valve stenosis (AS) is a common heart problem that is particularly prevalent in the elderly population. For several decades, surgical 
aortic valve replacement has been the mainstay of treat-
ment for symptomatic AS, and it is considered a Class I 
recommendation in international guidelines.1 In selected 
individuals, the surgery brings considerable improvement 
of symptoms and in life expectancy.1 Nonetheless, there 
is a considerable proportion of elderly individuals with 
AS to whom a surgical alternative is not offered due 
to the high or prohibitive risk.1
Due to the unmet need for treatment of this high-
risk subgroup, minimally invasive procedures began to 
emerge. The transcatheter aortic valve implant (TAVI) is 
a percutaneous procedure which is a therapeutic op-
tion for patients with AS with no surgical possibility.2
Since the first TAVI in 2002, over 70,000 procedures 
were performed with a high rate of success. However, 
the basic demographic data and the characteristics 
of the procedure, as well as the clinical results, may 
differ in Argentina when compared with those found 
in the rest of the world. To date, there is only limited 
data regarding the feasibility and safety of TAVI in this 
country.3-5 Thus, this study presents an initial experience 
with TAVI using the Medtronic CoreValve® self-expanding 
system (Medtronic Inc. – Minneapolis, USA).
METHODS
Patient population and diagnostic procedures
Between March of 2009 and March of 2013, 51 
consecutive patients with severe symptomatic AS and 
high or prohibitive surgical risk underwent TAVI at 
this institution.
A multidisciplinary team determined the eligibility for 
TAVI based on the clinical situation and transesophageal 
echocardiography (TEE), on selective coronary angiog-
raphy, on aortography, and on iliofemoral angiography. 
TEE was performed in all patients, whereas multiple 
detectors computed tomography (MDCT) was performed 
in only a few, to assess the anatomy of the aortic root 
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– Minneapolis, Minnesota, United States) prosthesis. Briefly, 
the CoreValve® prosthesis consists of porcine pericardial 
tissue mounted on a self-expanding nitinol stent.
The procedures were initially performed with a 18F 
release catheter which was later enhanced by an Ac-
cuTrak® stabilizing membrane. Three sizes of prostheses 
were available (26, 29, and 31 mm) for the sizes 20 
and 29 mm of the aortic valve annulus. Details of the 
device and technical aspects of the procedure were 
previously published.7
The transarterial access was obtained percutane-
ously or by surgical incision. After obtaining vascular 
access, a guide wire of 0.35” (a normal J wire or a 
straight wire, when appropriate) was positioned in the 
left ventricle and two pigtails were placed in the as-
cending aorta and left ventricle, to perform simultaneous 
measurements of pressure and transvalvular gradient 
evaluation. The intraventricular guide wire was then 
exchanged for a high support wire with a customized 
curve, and positioned at the apex. The positioning and 
implantation of the prosthetic valve into the aortic ring 
were guided by fluoroscopy and TEE. The pre-dilation 
was left to the discretion of the operator. The gradual 
release of the prosthesis was taken by retraction of the 
sheath. A post-dilation was performed in cases of device 
underexpansion. The femoral access was surgically or 
percutaneously closed with two Perclose ProGlide® 
Suture-Mediated 6F Closure Systems (Abbott Vascular 
– Redwood City, United States).
Medication
All patients were medicated with acetylsalicylic acid 
before the procedure and continued to receive this drug 
indefinitely. The patients were also medicated with a 
loading dose of clopidogrel 300 mg. The maintenance 
dose of clopidogrel, administered for three months, was 
75 mg. During the procedure, unfractionated heparin 
was administered according to the patient’s weight, to 
achieve activated clotting time ≥ 250 sec.
Follow-up
Clinical and echocardiographic examinations were 
performed before hospital discharge, at 30 days, six 
months, and 12 months. The results were analyzed 
according to updated standard outcomes, defined by 
VARC-2 criteria.
Statistical analysis
Qualitative variables were expressed as percent-
ages, and quantitative variables as mean ± standard 
deviation, or as median (interquartile range [IQ], 25% 
to 75%). Categorical variables were compared with the 
chi-squared test. To compare the mean and maximum 
serial gradients, the t-paired test was used. The statisti-
cal analysis was performed using SPSS, version 21.0 
(IBM – Armonk, New York, United States).
RESULTS
Patient characteristics
The baseline characteristics are summarized in Table 
1. All patients had dyspnea, and most of them at rest 
or after minimal physical activity. The mean age was 
82 ± 6 years, 49% were female, 19% were diabetic, 
and 21% had chronic renal failure. The mean logistic 
EuroSCORE was 17.4 ± 11.4%, and 17% of patients 
had comorbidities not measured in the current surgical 
risk scores: four patients (7.8%) had porcelain aorta, 
three patients (5.8%) had severe chest wall deformity or 
previous thorax irradiation, and one patient underwent 
TABLE 1 
Patient characteristics (n = 51)
Age, years 82 ± 5.7
Female, n (%) 25 (49)
Body mass index, kg/m2 27 ± 4
Logistic EuroSCORE, % 17.4 ± 11.7
STS score*, % 10.2 ± 9
NYHA functional class **, n (%) 
II 6 (11.8)
III 18 (35.3)
IV 27 (52.9)
Hypertension, n (%) 43 (84.3)
Dyslipidemia, n (%) 35 (68.6)
Diabetes mellitus, n (%) 10 (19.6)
Smoking, n (%) 15 (29.4)
Prior stroke, n (%) 4 (7.8)
Atrial fibrillation, n (%) 11(21.6)
Permanent pacemaker, n (%) 6 (11.8)
Previous angioplasty, n (%) 16 (31.4)
Previous heart surgery, n (%) 8 (15.7)
Chronic obstructive pulmonary 
disease, n (%) 
5 (9.8)
Chronic renal failure, n (%) 11 (21.6)
Peripheral arterial disease, n (%) 11 (21.6)
Fragility, n (%) 17 (33.3)
Echocardiographic findings
Aortic valve area, cm2 0.5 ± 0.2
Mean aortic valve gradient, mmHg 50 ± 10
Left ventricle ejection fraction, % 55 ± 13
Aortic annulus size, cm2 23 ± 2
*STS: Society of Thoracic Surgeons. The STS score measures 
the risk at the time of cardiovascular surgery, on a scale from 
zero to 100. A number in the upper range of 10% indicates a 
very high surgical risk; ** NYHA functional class: Functional 
class from New York Heart Association.
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previous liver transplantation in immunosuppressive 
therapy. Table 1 shows the baseline echocardiographic 
parameters, illustrating the severity of AS.
Procedure
Of a total of 51 patients, 82.4% underwent elec-
tive procedures and the remaining were submitted to 
urgent procedures. The total percutaneous access was 
performed in 43% of cases, and most procedures (50/51) 
were guided by TEE (Table 2).
CoreValve® devices of 26 and 29 mm were im-
planted in 44% and 52% of patients, respectively. The 
CoreValve® device of 31 mm has been available since 
December 2012, and was used in two cases (4%). 
Pre-dilation with balloon was performed in 28 patients 
(54.9%), while 19 (37.3%) required post-dilation due to 
valve underexpansion immediately after its implantation.
84.3% of patients (43/51) achieved success with 
the device. A dramatic decrease of the maximum (83 
± 22 to 13 ± 5 mmHg; P < 0.001) and mean (50 ± 10 
to 6.4 ± 2.6 mmHg; P < 0.001) transvalvular gradients 
was observed by echocardiography immediately after 
the procedure. At the end of the procedure, no patient 
showed severe aortic regurgitation; its occurrence was 
moderate in six (11.8%) and mild in 32 patients (62.7%).
Two patients died during the procedure (one due 
to ring rupture during the pre-dilation, and the other 
immediately before the pre-dilation, due to a secondary 
hemodynamic instability). Two patients required a second 
valve (one of them due to prosthesis embolization in 
the aortic arch and the other due to a deep annular 
implant associated with severe aortic regurgitation).
Results in-hospital and at 30 days
The median hospital stay was six days (IQ = 5-8.8), 
and 32.6% of patients received a permanent pacemaker. 
The in-hospital mortality and at 30 days for all causes 
were 7.8% (4/51) and 9.8% (5/51), respectively. Two 
patients (3.9%) had ischemic stroke. Major vascular 
complications occurred in three patients (5.9%).
Follow-up
The initial reduction of the observed maximum and 
mean gradients, after the procedure, was maintained 
throughout the follow-up (Figure 1). 
The survival at six months and one year was 86.3% 
and 84.4%, respectively. The NYHA functional class 
improved significantly after TAVI and remained low 
in the long-term follow-up (Figure 2). At one year, no 
patient had severe aortic regurgitation, whereas 5/43 
patients (11.6%) had moderate aortic regurgitation.
DISCUSSION
Symptomatic AS is a heart disease associated with 
an impaired functional status and that portends a poor 
prognosis.1 For decades, older individuals with this 
disease did not receive an appropriate treatment, due 
TABLE 2 
Results of procedure and follow-up (n = 51)
Results
Procedure, n (%) 
Elective 42 (82.4)
Urgent 9 (17.6)
Prosthesis labelled size in mm, n (%) 
26 22 (43.1)
29 26 (51.0)
31 2 (3.9)
General anesthesia, n (%) 51 (100)
Transesophageal echocardiography,  
n (%) 
50 (98.0)
Fully percutaneous procedure, n (%) 22 (43.1)
Pre-dilation, n (%) 28 (54.9)
Post-dilation, n (%) 19 (37.3)
Success of the device*, n (%) 43 (84.3)
Death, n (%)
Intraprocedure 2 (3.9)
In-hospital 4 (7.8)
30 days 5 (9.8)
Six months 7 (13.7)
One year 8 (15.7)
Aortic regurgitation, n (%) 
≥ Grade 2 postprocedure 6 (11.6)
≥ Grade 2 within 1 year 5 (9.8)
Stroke, n (%) 2 (3.9)
* Success of the device is defined as a prosthesis implant 
without moderate/severe aortic regurgitation or death.
Figure 1 – Assessment of baseline, mean and maximum transvalvular 
aortic gradients by serial echocardiography, at 30 days, six months, 
and one year of follow-up. 
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to the presence of comorbidities and to the high surgi-
cal risk. The present study reports an initial experience 
with TAVI, a minimally invasive alternative procedure 
for the definitive treatment of patients with symptomatic 
AS who are at high or prohibitive surgical risk.
In the present study, the mortality at 30 days was 
9.8%, which is consistent with other TAVI registries 
that used CoreValve® systems (United Kingdom regis-
try: 7.1%; France registry: 12.7%; France-2 registry: 
9.4%; and Germany registry: 12.4%),8-10 reflecting the 
feasibility and safety of the procedure in the patient 
population in the clinical practice with AS, which 
usually remains without a proper treatment. The mor-
tality rate in this study at 30 days was slightly higher 
than that observed in a recently published Brazilian 
trial (6.7%). Unlike the present study, the authors 
performed TAVI without pre-dilation with balloon, 
which may have helped to improve the short-term 
survival of their patients.4 Subsequently, a Brazilian 
TAVI registry (n = 112) with patients undergoing a 
mandatory pre-dilation, showed a similar mortality 
(9.4%).3 Also in line with previous registries,8,11 the 
survival at one year was 84.4%. The present study 
also reported a significant decrease in the gradient 
of the aortic valve, which resulted in a sustained de-
crease in heart symptoms after TAVI. Therefore, after 
an initial exposure to a risk, patients who survived 
had a considerable improvement in quality of life 
and an excellent clinical outcome in the long-term, 
confirming the durability of the device.
In the present study, the high surgical risk (logistic 
EuroSCORE: 17.4 ± 11.4%) would have contraindicated 
the surgical valve replacement procedure or led to 
excessive mortality and morbidity consequent to the 
surgery. Apparently, the risk of TAVI is reasonable, 
given the absence of a definitive alternative treatment 
and the poor prognosis observed with an exclusive 
medical treatment. According to contemporaneous TAVI 
registries,12-15 the number of cardiovascular adverse 
events decreased with advances in device technology 
and the growing experience of the surgeons and of 
the heart team.
There is considerable evidence indicating that 
the paravalvular aortic regurgitation after TAVI may 
lead to a worse prognosis.16,17 According to previ-
ous series, the paravalvular aortic regurgitation after 
TAVI is present in 48 to 93% of cases,18,19 while 
the rate of moderate aortic regurgitation is around 
14-21%.18,19 In line with these trials, 12.2% of the 
present patients had moderate aortic regurgitation 
after TAVI. Likewise, a Brazilian experience in 112 
patients showed a rate of moderate/severe aortic 
regurgitation of 11.6% after the procedure.3 In the 
initial experiences with TAVI, the majority of centers 
conducted pre-procedural basal assessments with 
two-dimensional echocardiography; however, several 
trials have subsequently demonstrated that often the 
aortic annulus is an elliptical structure and that, in 
consequence, the two-dimensional echocardiographic 
evaluation is inaccurate, because it assumes that the 
ring is circular. More recente trials shown that a more 
precise assessment of the aortic annulus allows for a 
better selection of the prosthesis size, which translates 
into a smaller paravalvular leak.20,21 Consequently, 
current guidelines indicate that pre-assessment pro-
cedures should be performed with three-dimensional 
echocardiography or MDCT, to obtain an accurate 
measurement of the perimeter and the area of the 
ring.1,20,21 Moreover, a new generation of prostheses 
with better sealing proprieties and the ability to be 
repositioned and recaptured will probably be able 
to reduce the paravalvular leak.22-24
The implantation of a pacemaker remains a cause 
for concern, especially after the implantation of Cor-
eValve® device. According to previous trials with Cor-
eValve®, approximately one-third of patients require a 
permanent pacemaker.25-28 Interestingly, the need for a 
permanent pacemaker appears to be not detrimental to 
the survival of patients undergoing TAVI.27,29 The pres-
ence of a new left bundle branch block and/or a QRS 
duration > 120 ms after release of the prosthesis can 
be a predictor for the development of a high degree 
AV block; besides, this finding will help guiding the 
clinical decision. However, accurate clinical indications, 
related to the implantation of a pacemaker after TAVI, 
are still under development.
So far, the reported rates of ischemic stroke after 
TAVI have remained around 1 to 10%.30,31 In the present 
studies, two patients suffered an ischemic stroke, one 
with a fatal hemorrhagic transformation in the context 
of a systemic inflammatory response syndrome and of 
Figure 2 – Mortality rate and NYHA functional class at 30 days, six 
months, and one year of follow-up. 
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severe thrombocytopenia. The second patient also had 
a hemorrhagic transformation, but with mild neurologi-
cal involvement.
CONCLUSIONS
In this preliminary experience from a single center, 
treating patients with AS and high or prohibitive surgical 
risk through TAVI using the self-expanding CoreValve® 
system was considered feasible and safe, leading to 
a sustainable improvement of heart symptoms. After 
overcoming the initial risk of death and stroke, the 
procedure ensured a good clinical outcome in the 
long term.
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